In conclusion, SP-D and KL-6 are useful biomarkers for differentiating patients with honeycombing on HRCT into the stable and progressive stages, which would inform clinical implication for IPF. The gene discussed is SFTPD; the disease is idiopathic pulmonary fibrosis.